Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Concentrations of Remifentanil for Extubation (REMEX)

16 de marzo de 2016 actualizado por: LUIS ALBERTO TAFUR B, Seganest

Effect of Two Plasma Concentrations of Remifentanil Through Target Controlled Anesthesia on Frequency and Intensity of Coughing During Extubation: Randomized Controlled Clinical Trial

Condition of the State: (terminated, recruiting, etc.) Terminated

Study Design: Main Objective:

Compare the frequency and intensity of coughing at the time of extubation with two infusions of remifentanil that predict a plasma concentration (PC) of 3 - 4 and 2 - 3 ng/ml, through the technique of target controlled anesthesia

Descripción general del estudio

Estado

Terminado

Condiciones

Descripción detallada

Phase of the study:

Phase IV

Intervention:

Drug: U Extubation

Other Names:

Concentration 2 - 3 ng/ml Dose of remifentanil according to the randomization: Letter U between 2 - 3 ng/ml. The infusions that were used to reach the (PC) target were: Group U = 2 - 3 ng/ml. 20 years old - 6.0 mcg/Kg/h, 30 years old - 5.7 mcg/Kg/h, 40 years old - 5.3 mcg/kg/h, 50 years old - 5.0 mcg/kg/h, 60 years old - 4.6 mcg/kg/h, 70 years old - 4.3 mcg/kg/h, 80 years old - 4.0 mcg kg/h.

Drug: Extubation T

Other Names:

Concentration 3 - 4 ng/ml Dose of infusion of remifentanil to reach a (PC) 3 - 4 ng/ml, in the following manner: The assistant placed the infusion balloon in such a way that it could not be seen by the treating anesthesiologist, he proceeded to open the corresponding wrapping according to the consecutive which corresponds to the patient. The remifentanil dose was adjusted according to the randomization: Group T = 3 - 4 ng/ml. 20 years old - 9.0 mcg/Kg/h, 30 years old - 8.5 mcg/Kg/h, 40 years old - 8.0 mcg/kg/h, 50 years old - 7.5 mcg/kg/h, 60 years old - 7.0 mcg/kg/h, 70 years old - 6.5 mcg/kg/h, 80 years old - 6.0 mcg kg/h.

Number of arms:

2

Masking:

The patient had masking with regards to the anesthetic procedure from the unfamiliarity per se of the same and by agents used in this that induced anxiolysis and hypnosis.

To guarantee the masking to the viewer, which was the treating anesthesiologist, a nurse was trained in the adjustment of the infusion balloon. Ten minutes before concluding the procedure and by request of the anesthesiologist, the nurse proceeded to locate balloon in such a way that the infusion could not be seen by the anesthesiologist, then opened the envelope and adjusted the infusion according to the randomization (U) o (T). The evaluation of the cough, its intensity and the Ramsay were under the care of the anesthesiologist, who was unaware of the awakening infusion.

Allocation:

Two were allocated for the use: Concentration of remifentanil of 2 - 3 ng/ml (group U) and concentration of remifentanil of 3 - 4 ng/ml (group T).

Recruitment:

A patient was recruited between the period of January 2011 and July 2012.

Tipo de estudio

Intervencionista

Inscripción (Actual)

110

Fase

  • Fase 4

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Valle del Cauca
      • Santiago de Cali, Valle del Cauca, Colombia, 288 00
        • Instituto Para Niños Ciegos y Sordos del Valle del Cauca

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 70 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • All patients aged 18-70 years
  • Risk Scale American Society of Anaesthesiologists physical status classification (ASA) I and II
  • Undergoing elective ear surgery

Exclusion Criteria:

  • Patients who are contraindicated remifentanil
  • Patients undergoing emergency surgery
  • Pulmonary Pathology (ASTHMA - COPD)
  • Index of body mass greater than 35
  • Background of respiratory failure three weeks prior to the procedure
  • Smokers

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Extubation U
Remifentanil concentration between 2 - 3 ng/ml.

Dose of remifentanil according to the randomization; the infusions that were used to reach the PC target were:

  • 20 years old - 6.0 mcg/Kg/h
  • 30 years old - 5.7 mcg/Kg/h
  • 40 years old - 5.3 mcg/kg/h
  • 50 years old - 5.0 mcg/kg/h
  • 60 years old - 4.6 mcg/kg/h
  • 70 years old - 4.3 mcg/kg/h
  • 80 years old - 4.0 mcg kg/h.
Otros nombres:
  • Ultiva
Experimental: Extubation T
Remifentanil concentration between 3 - 4 ng/ml

Dose of infusion of remifentanil to reach a PC 3 - 4 ng/ml, in the following manner:

The assistant placed the infusion balloon in such a way that it could not be seen by the treating anesthesiologist, he proceeded to open the corresponding wrapping according to the consecutive which corresponds to the patient.

The remifentanil dose was adjusted according to the randomization:

  • 20 years old - 9.0 mcg/Kg/h
  • 30 years old - 8.5 mcg/Kg/h
  • 40 years old - 8.0 mcg/kg/h
  • 50 years old - 7.5 mcg/kg/h
  • 60 years old - 7.0 mcg/kg/h
  • 70 years old - 6.5 mcg/kg/h
  • 80 years old - 6.0 mcg kg/h.
Otros nombres:
  • Ultiva

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Cough
Periodo de tiempo: It is evaluated by the scale of cough over a two hour period after surgery: is assessed at 5 minutes turned off the halogenated inhalation anesthetics, thereafter every minute until the patient responds to verbal stimulus and can be extubated

Number of episodes and duration of cough that occur when the patient responds to verbal stimulus and extubated.

Cough Scale

  • Grade 0 = No cough
  • Grade 1 = Mild (only episode of cough)
  • Grade 2 = Moderate (more than 1episode of cough during less than 5 seconds)
  • Grade 3 = Severe (More than one episode of cough that lasted more than 5 seconds or purposeless movements of the extremities).
It is evaluated by the scale of cough over a two hour period after surgery: is assessed at 5 minutes turned off the halogenated inhalation anesthetics, thereafter every minute until the patient responds to verbal stimulus and can be extubated

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Wake time.
Periodo de tiempo: During two hours after surgery, five minutes after turning off halogenated inhaled anesthetics, then every minute until the patient opens his eyes and is extubated.

When vaporizer where closed until the patient responds to the verbal stimulus and is extubated.

Defined as the time taken to open eyes after having turned off the halogenated inhalation anesthetics.

During two hours after surgery, five minutes after turning off halogenated inhaled anesthetics, then every minute until the patient opens his eyes and is extubated.
Ramsay scale at the time of extubation
Periodo de tiempo: During two hours after surgery, the estimated time period during which the event was assessed five (5) minutes after every minute, until answered

Ramsay scale: score objective system for measuring drug-induced sedation

  • Score 1: Anxious or restless or both
  • Score 2: Cooperative, orientated and tranquil
  • Score 3: Responding to commands
  • Score 4: Brisk response to stimulus
  • Score 5: Sluggish response to stimulus
  • Score 6: No response to stimulus
During two hours after surgery, the estimated time period during which the event was assessed five (5) minutes after every minute, until answered

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: LUIS A TAFUR, MD, Seganest
  • Director de estudio: Eduardo Lema, MD, Seganest

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de enero de 2011

Finalización primaria (Actual)

1 de enero de 2011

Finalización del estudio (Actual)

1 de julio de 2012

Fechas de registro del estudio

Enviado por primera vez

27 de agosto de 2013

Primero enviado que cumplió con los criterios de control de calidad

16 de marzo de 2016

Publicado por primera vez (Estimar)

17 de marzo de 2016

Actualizaciones de registros de estudio

Última actualización publicada (Estimar)

17 de marzo de 2016

Última actualización enviada que cumplió con los criterios de control de calidad

16 de marzo de 2016

Última verificación

1 de marzo de 2016

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

No

Descripción del plan IPD

The individual data of the participants (IPD) were only available to the ethics committee of the institution.

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir